Table 1.
Demographics and disease characteristics.
| Sample size | Value | |
|---|---|---|
| Gender [men, n (%)] | 111 | 68 (61) |
| Age in years [median (range)] | 111 | 65 (38–84) |
| Work [n (%)] | 110 | |
| Not working | 88 (80) | |
| Part-time job | 17 (15) | |
| Full-time job | 5 (5) | |
| Marital status [n (%)] | 110 | |
| Single | 22 (20) | |
| Relation/married, living together | 84 (76) | |
| Relation, living apart | 4 (4) | |
| Education [n (%)] | 109 | |
| Primary school | 10 (9) | |
| Secondary school | 41 (38) | |
| Lower vocational education | 30 (27) | |
| Higher education | 28 (26) | |
| PD disease duration [n (%)] | 111 | |
| 5–10 years | 31 (28) | |
| More than 10 years | 80 (72) | |
| Self-reported Hoehn and Yahr stage [n (%)] | 109 | |
| 0 | 3 (3) | |
| 1 | 13 (12) | |
| 2 | 9 (8) | |
| 3 | 52 (48) | |
| 4 | 24 (22) | |
| 5 | 8 (7) | |
| Treatment [n (%)*] | 111 | |
| CSAI | 20 (18) | |
| DBS | 65 (59) | |
| LCIG | 42 (38) | |
| Years of treatment | 111 | |
| 0–1 | 19 | |
| 1–2 | 60 | |
| 2–3 | 32 |
CSAI, continuous subcutaneous Apomorphine infusion; DBS, deep brain stimulation; LCIG, Levodopa-Carbidopa intestinal gel.
*
The total number exceeds 111 as some patients had undergone more than one of the advanced treatment options.